Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CAJoseph P. Garay, James E. Korkola, Kaylyn L. Devlin et al.|Breast Cancer Research|2021Cited by 21